Muireann Bolger

Key details

Muireann Bolger is deputy editor of World Intellectual Property Review and Life Sciences Intellectual Property Review in London, where she covers trademarks, brands, as well as wider developments across the intellectual property sector.

She regularly attends and covers major IP conferences around the world, reporting on the latest legal, commercial and policy developments and interviewing leading figures from across the sector. She has also co-authored industry reports with leading IP organisations, including the International Trademark Association (INTA).

She is the editor of the website’s Community & Inclusion channel and the annual Influential Women in IP list, which celebrates the achievements and contributions of leading women across the IP sector.

Originally from Ireland, Muireann has nearly two decades of experience reporting on brand developments, strategy, and wider business issues.

In her current role, she writes and edits news and analysis for an international audience of IP professionals, while also championing inclusion within the profession.

Reset all filters
Article Type
Channels & Sectors
Geography
Company
Refine search
Total results: 415

Articles by Muireann Bolger

PTAB: Roche patent can’t evade IPR under Fintiv
Pharma
Roche unit Chugai failed to persuade the US Patent Trial and Appeal Board that it should not institute inter partes reviews of a patent covering Actemra, a treatment for arthritis under the NHK/Fintiv rule.   11 January 2022
AstraZeneca inks $730m licensing deal for rare heart disease treatment
Biotech
Alexion, AstraZeneca’s rare disease group, has entered into an exclusive licensing agreement with Neurimmune AG for NI006, an antibody in development for the treatment of the heart condition, transthyretin amyloid cardiomyopathy.   11 January 2022
Hatch-Waxman can’t offer ‘safe harbour’ defence in gene therapy case
Americas
Sarepta Therapeutics won’t be able to rely on a “safe harbour” provision to protect its gene therapy invention from a patent infringement suit from biotech Regenxbio and the University of Pennsylvania, a Delaware court has ruled.   6 January 2022
Biotech
Biotech Allele has dropped its lawsuit accusing Pfizer and BioNTech of infringing technology covering a fluorescent protein used in COVID-19 vaccines.   6 January 2022
Generics
Hikma Pharmaceuticals has secured a win in its “skinny label” patent suit with Amarin Pharmaceuticals, following a ruling handed down by a federal court in the state of Delaware.   6 January 2022
Pharma
Former GlaxoGlaxoSmithKline scientists conspired to steal trade secrets to benefit the Chinese firm, Renopharma, according to the US Department of Justice.   4 January 2022
Americas
Novartis Pharmaceuticals has prevailed against China’s HEC Pharm at the US Court of Appeals for the Federal Circuit, after a majority panel of judges held that a patent covering the multiple sclerosis drug Gilenya was valid.   4 January 2022
Generics
Gilead, Bristol-Myers Squibb and Janssen are facing accusations that they suppressed competition in the market for drugs used to treat the human immunodeficiency virus.   16 December 2021
Americas
Multinational 3M has suffered a setback in its litigation campaign against the distributors of N95 masks after a US judge found in favour of arguments made by one of its opponents.   14 December 2021
Americas
Mylan has been allowed to revisit a decision holding that it infringed patents covering AstraZeneca's inhaler asthma treatment, Symbicort.   9 December 2021

Not finding what you're looking for, please try resetting your applied search and filters,
or try the
full site search.